Acumen Pharmaceuticals

Leadership has deep CNS/AD experience: CEO Daniel O’Connell, CMO Eric Siemers, and President/Chief Development Officer James Doherty; plus an experienced board chaired by former Celgene EVP George Golumbeski. Execution on enrollment and study operations has been solid (ALTITUDE‑AD completed enrollment ahead of schedule).

Insider ownership appears modest and SBC is typical for stage. We credit relevant expertise, but retain skepticism until pivotal clinical outcomes are delivered.